Biocon Pays $3.3bn For Viatris Biosimilars Business
‘Transformational’ Deal Offers Biocon Portfolio, Pipeline And Global Presence
Biocon Biologics will pay up to $3.3bn to acquire the global biosimilars business of Viatris, in a long-rumored deal that will create a vertically-integrated biosimilars giant with annual sales approaching $1bn.
